RESUMEN
Objective To observe Shenling-Baizhu granule combined with saccharomyces boulardii treatment for pediatric antibiotic associated diarrhea (AAD). Methods A total of 146 children with AAD were randomly divided into the control group (n=73) and the observation group (n=73). The control group received the saccharomyces boulardii, and the observation group received saccharomyces boulardii and Shenling-Baizhu granule, with a course of 5 days. The CD4 and CD8 T lymphocytes were detected by flow cytometry. The stool frequency, stool frequency recovery time, and clinic effects were compared. Results The stool frequency (3.0 ± 0.4 times/d vs. 3.6 ± 0.4 times/d, t=2.624), stool frequency recovery time (3.2 ± 0.6 d vs. 4.5 ± 0.8 d, t=2.641), and recovery time (4.1 ± 0.8 d vs. 5.3 ± 1.1 d, t=2.522) in observation group were significantly lower than those in control group ( P＜0.05). After the treatment, the CD4+(38.65% ± 5.74% vs. 33.72% ± 5.23%, t=2.452), CD4+/CD8+(1.92 ± 0.38 vs. 1.45 ± 0.26, t=2.483) of the observation group was significantly higher than those of the control group, and the CD8+(20.15% ± 3.16% vs. 23.21% ± 3.44%, t=2.483) of the observation group was significantly lower than this of the control group (P＜0.05). The rate of clinic effects was 93.2% (68/73) in observation group, which was higher than 80.8% (59/73) in control group (χ2=2.446, P＜0.05). Conclusions The Shenling-Baizhu granule combined with saccharomyces boulardii could enhance the immune function in children with AAD with significant clinical efficacy.
RESUMEN
Objective To observe the effect of Succinate injection combined with Bifico on the myocardial enzymes changes of the children with rotavirus enteritis.Methods A total of 146 children with rotavirus enteritis were enrolled and included in this study. Children were randomly divided into the control group (n=73) and the observation group (n=73). The control group was received Bifico on the basis of routine treatment, and observation group was received Succinate injection combined with Bifico. The IL-17, IL-6, TNF-?, LDH, CK, and CKMB was detected by ELISA. The rates of clinical effects was compared.Results After treatment, the IL-17 (22.35 ± 4.21 ng/mlvs. 30.24 ± 6.07 ng/ml,t=2.395), IL-6(31.26 ± 6.14 ng/mlvs. 43.72 ± 8.22 ng/ml,t=2.347), TNF-? (35.62 ± 6.24 ng/mlvs. 49.18 ± 8.72 ng/ml,t=2.421), LDH (135.16 ± 31.25 U/Lvs. 174.08 ± 40.22 U/L,t=2.373), CK (37.82 ± 7.39 U/Lvs. 50.21 ± 11.16 U/L,t=2.385), and CKMB (90.14 ± 11.63 U/Lvs. 113.22 ± 18.35 U/L,t=2.392) in the observation group were lower than those in the control group (P<0.05). The rates of clinical effects was 94.5% (69/73) in the observation group and 83.6% (61/73) in the control group. There was significant difference between the two groups (χ2=2.352,P=0.047).Conclusions The Succinate injection combined with Bifico could reduce the inflammatory indices and alleviate the myocardial injury in the RVE patients.